Investor Presentaiton

Advancing and enhancing our deep pipeline Oncology Highlights • KEYNOTE-671: Received FDA approval for KEYTRUDA for the neoadjuvant and adjuvant treatment of certain patients with resectable non-small cell lung cancer • ESMO: Compelling data presented across a wide range of molecules, tumor types and indications Cardiometabolic Highlights . • Sotatercept: FDA accepted for priority review the BLA for sotatercept for the treatment of adults with pulmonary arterial hypertension based on STELLAR ⚫ MK-0616: Started Phase 3 program for oral PCSK9 inhibitor candidate MERCK 7

View entire presentation